MARKET

TENX

TENX

Tenax Therapeut
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.230
+0.180
+17.14%
After Hours: 1.240 +0.01 +0.81% 17:59 12/03 EST
OPEN
1.060
PREV CLOSE
1.050
HIGH
1.350
LOW
1.060
VOLUME
1.32M
TURNOVER
--
52 WEEK HIGH
2.680
52 WEEK LOW
0.2500
MARKET CAP
15.52M
P/E (TTM)
-1.0225
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
TENX: FDA Meetings for Phase 3 Design
By John Vandermosten NASDAQ:TENX READ THE FULL TENX RESEARCH REPORT Third Quarter 2020 Financial and Operational Review Since Tenax Therapeutics, Incorporated’s (NASDAQ:TENX) second quarter update in August, the company has broadly shared the results from the H emodynamic E valuation of L evosimendan in P atients with PH-HFpEF (HELP) trial with the scientific and investment community. The most
Zacks Small Cap Research · 10h ago
Is Tenax Therapeutics Inc (TENX) A Good Stock To Buy?
Insider Monkey · 3d ago
Tenax Therapeutics Q3 EPS $(0.18) Up From $(0.33) YoY
Tenax Therapeutics (NASDAQ:TENX) reported quarterly losses of $(0.18) per share. This is a 45.45 percent increase over losses of $(0.33) per share from the same period last year.
Benzinga · 11/16 21:45
Tenax Therapeutics Reports Third Quarter 2020 Results and Provides Business Update
Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products for the critical care market, today reported financial results for the third quarter 2020 and provided a business update.
BusinessWire · 11/16 18:45
Acceleron's sotatercept shows positive action in mid-stage pulmonary arterial hypertension studies
Acceleron Pharma ([[XLRN]] -1.8%) announces new data from two Phase 2 clinical trials, SPECTRA and PULSAR, evaluating sotatercept in patients with pulmonary arterial hypertension ((PAH)).Preliminary results from 10 participants in
Seekingalpha · 11/13 16:29
Tenax Therapeutics Announces Presentation of 24-Hour HELP Study Results at the American Heart Association Scientific Sessions 2020
Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing, and commercializing products for the critical care market, today announced that data from the 24-hour open-label portion of the HELP (Hemodynamic Evaluation of Levosimendan in PH-HFpEF) Study will be presented during the American Heart Association (AHA) Scientific Sessions 2020 that is being conducted online from November 13, 2020 - November 17, 2020.
BusinessWire · 11/10 10:30
Tenax Therapeutics to Host Virtual R&D Webinar with Scientific Experts Highlighting HELP Study Results
Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products for the critical care market, today announced that it will host a virtual R&D webinar for analysts and investors on Wednesday, November 18, 2020 at 4:30 p.m. EST.
BusinessWire · 11/06 10:30
Tenax Therapeutics gains North American rights to oral levosimendan; shares +14%
Tenax Therapeutics (TENX) +14% premarket, has amended its existing licensing agreement with Orion Corporation to include the rights to develop and commercialize an oral formulation of levosimendan for use with Type 2
Seekingalpha · 10/15 13:04
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of TENX. Analyze the recent business situations of Tenax Therapeut through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average TENX stock price target is 3.000 with a high estimate of 4.000 and a low estimate of 2.000.
EPS
Institutional Holdings
Institutions: 44
Institutional Holdings: 4.13M
% Owned: 32.70%
Shares Outstanding: 12.62M
TypeInstitutionsShares
Increased
4
93.15K
New
12
1.90M
Decreased
2
213.00K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.07%
Pharmaceuticals & Medical Research
+0.39%
Key Executives
Chairman/Director
Ronald Blanck
President/Chief Financial Officer
Michael Jebsen
Chief Executive Officer/Director
Anthony DiTonno
Executive Vice President
Douglas Hay
Executive Vice President
Doug Randall
Other
Paula Bokesch
Director
Steven Boyd
Director
Keith Maher
Director
I. Keith Maher
Director
James Mitchum
Director
Gerald Proehl
Independent Director
Gregory Pepin
Independent Director
Chris Rallis
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About TENX
Tenax Therapeutics, Inc. is a specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing products for the critical care market. The Company's main product is levosimendan. Levosimendan is a calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure. Levosimendan represents therapeutic modalities for the treatment of Low Cardiac Output Syndrome (LCOS), septic shock and other critical care conditions. The therapeutic effects of levosimendan are mediated through increased cardiac contractility by calcium sensitization of troponin C, resulting in a positive inotropic effect, which is not associated with substantial increases in oxygen demand; opening of potassium channels in the vasculature smooth muscle, resulting in a vasodilatory effect on all vascular beds, and opening of mitochondrial potassium channels in cardiomyocytes, resulting in a cardioprotective effect.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Tenax Therapeutics Inc stock information, including NASDAQ:TENX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TENX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading TENX stock methods without spending real money on the virtual paper trading platform.